Skip to main content
Livermore
Livermore
ZHEN

Amylyx Pharmaceuticals, Inc.

AMLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001658551

In the last 90 days, Amylyx Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 206 institutions reported holding it in 13F filings for Q2 2026, worth $2.07B in total; no superinvestor holds it.

Q3 2023 vs. Q2 2023

How the institutions holding Amylyx Pharmaceuticals, Inc. changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of AMLX: Q2 2023 compared with Q3 2023
MeasureQ2 2023Of which not filed for Q3 2023Q3 2023Change
Holders1542170+18
Shares54.5M705.7K58.9M+5.09M (+9.5%)
Value$1.18B$15.2M$1.08B−$82.5M (−7.1%)

2 institutions that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.

New holders (34)

Institutions that held Amylyx Pharmaceuticals, Inc. at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to AMLX in Q3 2023
InstitutionSharesValue% of portfolio
Deep Track Capital, LP1,259,335$23.1M0.89%
Samlyn Capital, LLC1,164,897$21.3M0.38%
Saturn V Capital Management LLC886,143$16.2M6.79%
Octagon Capital Advisors LP695,000$12.7M2.24%
Gilder Gagnon Howe & Co LLC688,438$12.6M0.19%
Jupiter Asset Management Ltd649,736$11.9M0.13%
Primecap Management Co304,900$5.58M0.00%
Tri Locum Partners LP282,862$5.18M1.66%
Ally Bridge Group (NY) LLC272,690$4.99M5.86%
Algert Global LLC161,405$2.96M0.14%
Renaissance Technologies LLC150,100$2.75M0.00%
Connor, Clark & Lunn Investment Management Ltd.124,455$2.28M0.01%
DAFNA Capital Management LLC122,547$2.24M0.70%
Seven Eight Capital, LP59,891$1.10M0.13%
Legacy Advisors, LLC50,000$915.5K0.15%
Moore Capital Management, LP47,078$862.0K0.02%
Janney Montgomery Scott LLC42,784$783.0K0.00%
Dynamic Technology Lab Private Ltd37,494$687.0K0.07%
Nebula Research & Development LLC28,022$513.1K0.27%
UBS Asset Management Americas Inc27,800$509.0K0.00%
Axxcess Wealth Management, LLC26,151$478.8K0.02%
Knoll Capital Management, LLC24,772$453.6K0.47%
Capstone Investment Advisors, LLC22,829$418.0K0.01%
Millrace Asset Group, Inc.19,496$357.0K0.44%
Greenwood Capital Associates LLC17,352$317.7K0.05%
Teza Capital Management LLC11,797$216.0K0.04%
Rafferty Asset Management, LLC11,292$206.8K0.00%
Axq Capital, LP10,836$198.4K0.07%
XTX Topco Ltd10,099$184.9K0.03%
Quarry LP5,000$91.5K0.06%
Psagot Value Holdings Ltd. / (Israel)117$2.00K0.00%
Allworth Financial LP100$1.83K0.00%
Colonial Trust Co86$1.80K0.00%
Cutler Group LP50$00.00%

Sold out (16)

Institutions that held Amylyx Pharmaceuticals, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.

Institutions that sold out of AMLX in Q3 2023
InstitutionShares, Q2 2023Value, Q2 2023
Deerfield Management Company, L.P. (Series C)1,050,198$22.7M
Great Point Partners LLC968,795$20.9M
Lord, Abbett & Co. LLC244,493$5.27M
Soleus Capital Management, L.P.120,000$2.59M
Tang Capital Management LLC100,000$2.16M
Norges Bank84,100$1.81M
Bank of Montreal59,230$1.42M
First Trust Advisors LP54,115$1.17M
Virtu Financial LLC17,742$383.0K
Wellington Management Group LLP17,716$382.1K
Capital Fund Management S.A.12,281$264.9K
Bayesian Capital Management, LP10,050$216.8K
Tucker Asset Management LLC8,754$188.8K
PEAK6 Investments LLC1,500$32.4K
Connective Capital Management, LLC466$10.1K
Quadrant Capital Group LLC5$108

Not filed for Q3 2023 yet (2)

Institutions that held Amylyx Pharmaceuticals, Inc. at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding AMLX in Q2 2023 that haven't filed for Q3 2023
InstitutionShares, Q2 2023Value, Q2 2023
Pictet Asset Management SA601,646$13.0M
Tekla Capital Management LLC104,007$2.24M